These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24589534)

  • 21. [Biosimilar medicines. Scientific and legal disputes].
    Dorantes Calderón B; Montes Escalante IM
    Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilar and interchangable biologic medications.
    Simonson W
    Geriatr Nurs; 2016; 37(5):393-394. PubMed ID: 27637457
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA advisers recommend approval of biosimilar filgrastim.
    Traynor K
    Am J Health Syst Pharm; 2015 Feb; 72(4):262, 264. PubMed ID: 25631830
    [No Abstract]   [Full Text] [Related]  

  • 24. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.
    Heinemann L; Khatami H; McKinnon R; Home P
    Diabetes Technol Ther; 2015 Jul; 17(7):510-26. PubMed ID: 25789689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA approves first biosimilar, zarxio.
    Colwell J
    Cancer Discov; 2015 May; 5(5):460. PubMed ID: 25790983
    [No Abstract]   [Full Text] [Related]  

  • 26. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First biosimilar drug approved for sale in the United States.
    Hede K
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
    [No Abstract]   [Full Text] [Related]  

  • 28. Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters.
    Mielke J; Woehling H; Jones B
    Pharm Stat; 2018 May; 17(3):231-247. PubMed ID: 29424120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic Medicines Under the Microscope.
    Cauchi R
    State Legis; 2015; 41(7):12. PubMed ID: 26245000
    [No Abstract]   [Full Text] [Related]  

  • 30. Totality of the evidence at work: The first U.S. biosimilar.
    Holzmann J; Balser S; Windisch J
    Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barriers to biosimilar utilization in the United States.
    Dalpoas SE; Socal M; Proctor C; Shermock KM
    Am J Health Syst Pharm; 2020 Nov; 77(23):2006-2014. PubMed ID: 33091103
    [No Abstract]   [Full Text] [Related]  

  • 32. Factors influencing the economics of biosimilars in the US.
    Mehr SR; Brook RA
    J Med Econ; 2017 Dec; 20(12):1268-1271. PubMed ID: 28796564
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

  • 34. Biosimilars take center stage.
    Adams KT
    Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapy: Facing up to biosimilar agents--the ACR position.
    Scheinberg M
    Nat Rev Rheumatol; 2015 Jun; 11(6):322-4. PubMed ID: 25907701
    [No Abstract]   [Full Text] [Related]  

  • 36. Bracing for the biosimilar wave.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
    [No Abstract]   [Full Text] [Related]  

  • 37. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
    Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
    Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the United States' naming convention for biological products.
    Saunders J; Proctor C; Shermock KM
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):750-753. PubMed ID: 32319139
    [No Abstract]   [Full Text] [Related]  

  • 39. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar draft guidance issue by US FDA.
    Payne T
    Bioanalysis; 2012 Apr; 4(7):759. PubMed ID: 22512794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.